Background and Aims: Patients with interstitial pneumonia (IP) are at risk of developing pulmonary hypertension (PH), as the underlying condition worsens or becomes severer, thus further compromising their prognosis.
Methods: To describe three cases of IP-associated PH showing improvements in IP status and to explore the relationship between PH pathophysiology and IP status based on changes observed in PH.
Results: Case 1. A patient with collagen-vascular disease (CVD)-IP was diagnosed as having PH associated with anti-synthetase syndrome (ASS) and was started on bosentan therapy, which led to improvements in mPAP as well as in subjective symptoms over time. Indeed, the patient had had no acute exacerbations, with the serum markers of IP remaining low over 6 years following initiation of bosentan therapy. Case 2. A patient was diagnosed as having PH due to idiopathic pulmonary fibrosis (IPF) and was started on bosentan therapy, which led to clear improvements in PH, WHO functional class and maximum exercise tolerance on treadmill exercise testing. Case 3. A patient was diagnosed as having PH due to idiopathic interstitial pneumonia (IIP) and was started on nintedanib therapy, which led to clear improvements in the pathophysiology of IP and PH.
Conclusion: Improvements in the pathophysiology of IP appear to be accounted for largely by those in IP-associated PH. anti-ARS antibodies in the database of our institution from July 1995 to January 2018. These patients were divided into two groups, untreated group and treatment group. Between the groups, we compared about their backgrounds, findings on physical examination, laboratory data, pulmonary computed tomography (CT) findings and prognosis.
Results: All backgrounds such as age, sex, and smoking history were not statistically different. Seven patients presented with characteristic skin rashes of PM/DM only in treatment group. With regard to laboratory findings, the mean values of lactate dehydrogenase (LDH) and Creactive protein (CRP) in the first visit were higher in treatment group (LDH: 274.5 vs 201.0, CRP: 1.58 vs 0.06). Analysis of CT findings revealed that the ratio of nonspecific interstitial pneumonia pattern was higher in treatment group than untreated group (85.7% vs 42.9%). Sixteen IP patients were treated only with corticosteroids. The addition of immunosuppressive agents to corticosteroids was needed for remission of IP in 12 patients. Although three patients in treatment group were died of IP, the statistical differences of progression free survival by therapeutic regimens were not confirmed.
Conclusion:
The present study revealed that some IP patients positive for anti-ARS antibodies could be followed up without treatment. The value of LDH and CRP, and CT findings may help to decide whether the treatment is needed or not. 
